Pharmaceutical Technology

DECEMBER 7, 2023

GlobalData’s report assesses the drugs in the Protein Kinase C Theta Type pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

JULY 20, 2022

Researchers at Gladstone Institutes and UC San Francisco (UCSF) have discovered in a study that bromodomain and extraterminal (BET) proteins are vital for the body to fight Covid-19 infection. . The research also found that BET proteins play two distinct roles in affecting how the SARS-CoV-2 virus interacts with human cells. .

Protein 278

Protein Scientist Gene DNA 278

Pharmaceutical Technology

FEBRUARY 6, 2023

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263

Protein Research Antibody Immune Response 263

Bio Pharma Dive

MARCH 7, 2023

As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating cancer to pain. But biotech startups say there is still room to develop more.

Protein 360

Protein FDA Approval Drugs Development 360

Bio Pharma Dive

MARCH 11, 2024

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs 272

Drugs Protein Medicine Development 272

Bio Pharma Dive

AUGUST 25, 2021

The pharma has struck its second research pact focused on drugs that break down harmful proteins in as many years, this time with California biotech Lycia Therapeutics.

Protein 274

Protein Drugs Research 274

Bio Pharma Dive

AUGUST 2, 2022

It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.

Protein 264

Protein Development Drugs 264

Bio Pharma Dive

JANUARY 27, 2022

Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.

Protein 305

Protein Medicine Drugs 305

Bio Pharma Dive

MAY 18, 2023

At an investor day, executives highlighted an experimental inflammatory disease drug targeting the protein TL1A as important to their long-term growth prospects.

Drugs 359

Drugs Protein 359

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130

Protein Development Licensing Licensing 130

Bio Pharma Dive

MARCH 7, 2023

Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines. Its most advanced drug is already in early-stage human testing.

Drugs 362

Drugs Protein Medicine 362

Bio Pharma Dive

SEPTEMBER 20, 2023

Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

Drugs 263

Drugs Protein Scientist Development 263

Bio Pharma Dive

DECEMBER 16, 2022

The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

Protein 148

Protein Development Drugs 148

Pharmaceutical Technology

OCTOBER 25, 2023

The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport

Drugs 246

Drugs Protein 246

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins. These regions are critical for optimal interactions between proteins.

Protein 126

Protein Gene Bioassay DNA 126

Pharma Times

DECEMBER 20, 2023

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. Estimated to affect over 8.5 However, its relation to dopaminergic neuron death is unclear.

Protein 96

Protein Medicine Engineer Genetics 96

Bio Pharma Dive

AUGUST 28, 2023

GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.

Drugs 246

Drugs Protein Medicine 246

Bio Pharma Dive

AUGUST 23, 2023

Data inadvertently published from a closely watched lung cancer study suggest a drug blocking the protein TIGIT may help extend survival, a finding that boosted shares of other developers.

Drugs 246

Drugs Protein Development 246

Bio Pharma Dive

FEBRUARY 23, 2023

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

FDA Approval 273

FDA Approval Drugs Protein Marketing 273

Drug Discovery World

APRIL 17, 2024

Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR. This strategic transaction also further validates our innovative PROTAC protein degrader platform and its potential to deliver new treatments.”

Protein 52

Protein Licensing Licensing Sales 52

Bio Pharma Dive

DECEMBER 1, 2022

The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing.

Drugs 310

Drugs Protein 310

pharmaphorum

APRIL 26, 2024

Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensional surface.

Development 104

Development Protein Drugs 104

Pharmaceutical Technology

FEBRUARY 16, 2023

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors.

Protein 147

Protein Development Sales Business Development 147

Bio Pharma Dive

AUGUST 29, 2022

Sold as Pemazyre, the drug, which blocks well-known cancer proteins known as FGFRs, is now also cleared for use in certain patients with very rare and aggressive blood cancers.

Drugs 271

Drugs Protein 271

Bio Pharma Dive

MAY 1, 2023

The company was co-founded by, among others, Jamie Cate, husband of CRISPR pioneer Jennifer Doudna, and Kevan Shokat, a chemical biologist whose previous work helped lead to KRAS-targeting cancer drugs.

Protein 287

Protein Drugs 287

Drug Discovery World

JANUARY 22, 2024

A new infographic ‘ Four methods for thermal stability assessment of therapeutic proteins ‘ is now available to download for free. In this infographic, learn about four methods for thermal stability assessment of proteins – what they measure, what the data tells you, and their benefits and limitations.

Protein 52

Protein Drugs Development 52

Bio Pharma Dive

AUGUST 23, 2021

The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year.

Drugs 360

Drugs Protein 360

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Discover the top API protein and peptide companies in contract marketing. Technologies in the delivery of peptides and proteins. They are promising therapeutics for the treatment of a variety of metabolic and oncological disorders.

Protein 130

Protein Marketing Manufacturing Reagent 130

Drug Discovery World

FEBRUARY 12, 2024

million grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. Membrane proteins are crucial molecules on the surface of cells with numerous biological functions, such as sensing hormones or cell communication.

Research 105

Research Drugs Engineer Protein 105

Bio Pharma Dive

JULY 26, 2022

Known as tofersen, the drug failed in the main study being used to support its approval. But an apparent effect on a protein of interest in ALS research has Biogen convinced the treatment will pass muster with regulators.

Drugs 315

Drugs Protein Regulation Research 315

Drug Discovery World

MARCH 5, 2024

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.

Antibody 59

Antibody Protein Vaccination Vaccine 59

Drug Discovery World

NOVEMBER 14, 2022

New research about how cancer-related proteins bind copper ions opens up potential new drug targets to treat cancer. . Higher levels of copper also mean more active copper-binding proteins. . Higher levels of copper also mean more active copper-binding proteins. . Memo1 and metastatic cancer. Image caption: ?The

Protein 52

Protein Drugs Research Gene 52

Scienmag

FEBRUARY 18, 2022

CAMBRIDGE, MA — MIT chemists have discovered the structure of a protein that can pump toxic molecules out of bacterial cells. Proteins similar to this one, which is found in E. coli, are believed to help bacteria become resistant to multiple antibiotics.

Protein 82

Protein Bacteria Drugs Medicine 82

pharmaphorum

MARCH 13, 2024

Basecamp Research launches BaseFold, a deep learning model that it says surpasses benchmark tool AlphaFold2 and should accelerate AI-based drug discovery

Protein 115

Protein Drugs Research 115

Bio Pharma Dive

OCTOBER 24, 2023

The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.

Protein 300

Protein Medicine Drugs 300

Scienmag

JUNE 2, 2022

Mechanisms associated with a particular diabetes drug can also help to protect against Alzheimer’s disease, a study by researchers at Karolinska Institutet in Sweden and published in Neurology reports. The results indicate that the drug’s target protein can be an interesting candidate for the treatment of Alzheimer’s disease.

Protein 76

Protein Drugs Research 76

Drug Discovery World

NOVEMBER 7, 2023

As more and more R&D pipelines include PROTAC candidates — the race to bring successful and efficient protein degraders to the clinic is on. These targets present challenges in the biophysical characterisation of binary and ternary complexes, making developing effective degraders complicated.

Protein 52

Protein Development Drugs Research 52